617 related articles for article (PubMed ID: 33729394)
1. Immunity, virus evolution, and effectiveness of SARS-CoV-2 vaccines.
Belizário JE
Braz J Med Biol Res; 2021; 54(5):e10725. PubMed ID: 33729394
[TBL] [Abstract][Full Text] [Related]
2. N7-Methylation of the Coronavirus RNA Cap Is Required for Maximal Virulence by Preventing Innate Immune Recognition.
Pan R; Kindler E; Cao L; Zhou Y; Zhang Z; Liu Q; Ebert N; Züst R; Sun Y; Gorbalenya AE; Perlman S; Thiel V; Chen Y; Guo D
mBio; 2022 Feb; 13(1):e0366221. PubMed ID: 35073761
[TBL] [Abstract][Full Text] [Related]
3. Antiviral responses versus virus-induced cellular shutoff: a game of thrones between influenza A virus NS1 and SARS-CoV-2 Nsp1.
Khalil AM; Nogales A; Martínez-Sobrido L; Mostafa A
Front Cell Infect Microbiol; 2024; 14():1357866. PubMed ID: 38375361
[TBL] [Abstract][Full Text] [Related]
4. Inactivating Three Interferon Antagonists Attenuates Pathogenesis of an Enteric Coronavirus.
Deng X; Buckley AC; Pillatzki A; Lager KM; Faaberg KS; Baker SC
J Virol; 2020 Aug; 94(17):. PubMed ID: 32554697
[TBL] [Abstract][Full Text] [Related]
5. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
[TBL] [Abstract][Full Text] [Related]
6. Properties of Coronavirus and SARS-CoV-2.
Malik YA
Malays J Pathol; 2020 Apr; 42(1):3-11. PubMed ID: 32342926
[TBL] [Abstract][Full Text] [Related]
7. Structure of Nonstructural Protein 1 from SARS-CoV-2.
Clark LK; Green TJ; Petit CM
J Virol; 2021 Jan; 95(4):. PubMed ID: 33234675
[TBL] [Abstract][Full Text] [Related]
8. Quasi-species nature and differential gene expression of severe acute respiratory syndrome coronavirus 2 and phylogenetic analysis of a novel Iranian strain.
Ghorbani A; Samarfard S; Ramezani A; Izadpanah K; Afsharifar A; Eskandari MH; Karbanowicz TP; Peters JR
Infect Genet Evol; 2020 Nov; 85():104556. PubMed ID: 32937193
[TBL] [Abstract][Full Text] [Related]
9. SARS-CoV-2 will constantly sweep its tracks: a vaccine containing CpG motifs in 'lasso' for the multi-faced virus.
Oberemok VV; Laikova KV; Yurchenko KA; Marochkin NA; Fomochkina II; Kubyshkin AV
Inflamm Res; 2020 Sep; 69(9):801-812. PubMed ID: 32656668
[TBL] [Abstract][Full Text] [Related]
10. SARS-CoV-2 Proteins: Are They Useful as Targets for COVID-19 Drugs and Vaccines?
Mohammed MEA
Curr Mol Med; 2022; 22(1):50-66. PubMed ID: 33622224
[TBL] [Abstract][Full Text] [Related]
11. Emergence and Re-emergence of Human Coronaviruses: Spike Protein as the Potential Molecular Switch and Pharmaceutical Target.
Ahmad F; Kamal MA; Tekwani BL
Curr Pharm Des; 2021; 27(33):3566-3576. PubMed ID: 33327904
[TBL] [Abstract][Full Text] [Related]
12. Role of Structural and Non-Structural Proteins and Therapeutic Targets of SARS-CoV-2 for COVID-19.
Yadav R; Chaudhary JK; Jain N; Chaudhary PK; Khanra S; Dhamija P; Sharma A; Kumar A; Handu S
Cells; 2021 Apr; 10(4):. PubMed ID: 33917481
[TBL] [Abstract][Full Text] [Related]
13. The SARS-Coronavirus Infection Cycle: A Survey of Viral Membrane Proteins, Their Functional Interactions and Pathogenesis.
Wong NA; Saier MH
Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33525632
[TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 Isolates Show Impaired Replication in Human Immune Cells but Differential Ability to Replicate and Induce Innate Immunity in Lung Epithelial Cells.
Jiang M; Kolehmainen P; Kakkola L; Maljanen S; Melén K; Smura T; Julkunen I; Österlund P
Microbiol Spectr; 2021 Sep; 9(1):e0077421. PubMed ID: 34378952
[TBL] [Abstract][Full Text] [Related]
15. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
Elife; 2020 Oct; 9():. PubMed ID: 33112236
[TBL] [Abstract][Full Text] [Related]
16. SARS-CoV-2 Evolutionary Adaptation toward Host Entry and Recognition of Receptor O-Acetyl Sialylation in Virus-Host Interaction.
Kim CH
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32604730
[TBL] [Abstract][Full Text] [Related]
17. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
[TBL] [Abstract][Full Text] [Related]
18. A mutation in the coronavirus nsp13-helicase impairs enzymatic activity and confers partial remdesivir resistance.
Grimes SL; Choi YJ; Banerjee A; Small G; Anderson-Daniels J; Gribble J; Pruijssers AJ; Agostini ML; Abu-Shmais A; Lu X; Darst SA; Campbell E; Denison MR
mBio; 2023 Aug; 14(4):e0106023. PubMed ID: 37338298
[TBL] [Abstract][Full Text] [Related]
19. Epidemiology and Genomic Characterization of Two Novel SARS-Related Coronaviruses in Horseshoe Bats from Guangdong, China.
Li L; Zhang L; Zhou J; He X; Yu Y; Liu P; Huang W; Xiang Z; Chen J
mBio; 2022 Jun; 13(3):e0046322. PubMed ID: 35467426
[TBL] [Abstract][Full Text] [Related]
20. Cell Entry and Unusual Replication of SARS-CoV-2.
McCann N; Castellino FJ
Curr Drug Targets; 2022; 23(17):1539-1554. PubMed ID: 36239725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
